(Left to right) Amanda Moore, Luke Timmerman, Jenny Gordon, Debra Schaumberg, and Kanya Rajangam “Knowing what you want in the long run, not just from first-in-human or dose escalation, but the big picture strategy for your program, and how you can de-risk that, is one of the biggest challenges that goes along with a Phase I/II trial.” Emerging biotechnology companies face a unique landscape of risk when transitioning from preclinical development to clinical trials, compounded by resource...